Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane

被引：1

作者：

Ferician, Ovidiu ^{[1
]}

Cimpean, Anca Maria ^{[2
]}

Avram, Stefana ^{[2
]}

Raica, Marius ^{[2
]}

机构：

[1] Victor Babes Univ Med & Pharm, Angiogenesis Res Ctr, Dept Urol, Timisoara, Romania

[2] Victor Babes Univ Med & Pharm, Angiogenesis Res Ctr, Dept Microscop Morphol Histol, Timisoara, Romania

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 12期

关键词：

Endostatin; renal cell carcinoma; chick embryo chorioallantoic membrane; ENDOTHELIAL GROWTH-FACTOR; GENE-THERAPY; ENDOGLIN; EXPRESSION; MODEL; INHIBITORS; CANCER; CD105; VEGF;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rare and inconsistent data are reported for chorioallantoic tumor models of renal cell carcinoma and none of them has used endostatin as an inhibitory agent of tumor development. We aimed to perform a comparative analysis of tumor cells and blood vessels from renal cell carcinoma on endostatin-treated and non-treated chorioallantoic membrane (CAM) implants by the assessment of endoglin, vascular endothelial growth factor (VEGF) and smooth muscle actin expression. Endostatin triple action on tumor, endothelial and perivascular cells was observed in the present study. Differential impact of endostatin treatment on intratumor and peritumor blood vessels was noticed on the VEGF expression and behaviour of tumor cells between clear cell and papillary components of RCC. Based on our findings, a high tumor heterogenity response to endostatin has been highlighted. Interplay between VEGF, endoglin and endostatin in RCC could support a combined targeted therapy to improve prognosis of patients with RCC and reduce therapy resistance often developed by monotherapy.

引用

页码：6521 / 6528

页数：8

共 25 条

[11] Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy [J].

Fujita, Kazutoshi ;

Ujike, Takeshi ;

Nagahara, Akira ;

Uemura, Motohide ;

Tanigawa, Go ;

Shimazu, Kohki ;

Fushimi, Hiroaki ;

Yamaguchi, Seiji ;

Nonomura, Norio .

INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (05) :463-467

[12] An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer [J].

Gordon, Michael S. ;

Robert, Francisco ;

Matei, Daniela ;

Mendelson, David S. ;

Goldman, Jonathan W. ;

Chiorean, E. Gabriela ;

Strother, Robert M. ;

Seon, Ben K. ;

Figg, William D. ;

Peer, Cody J. ;

Alvarez, Delia ;

Adams, Bonne J. ;

Theuer, Charles P. ;

Rosen, Lee S. .

CLINICAL CANCER RESEARCH, 2014, 20 (23) :5918-5926

[13]

Guan Kao-peng, 2009, Zhonghua Wai Ke Za Zhi, V47, P737

[14] Cancer statistics, 2007 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Murray, Taylor ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66

[15]

Landt S, 2011, ANTICANCER RES, V31, P2651

[16] Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapy [J].

Mellon, Matthew J. ;

Bae, Kyung-Hee ;

Steding, Catherine E. ;

Jimenez, Juan A. ;

Kao, Chinghai ;

Gardner, Thomas A. .

HUMAN GENE THERAPY, 2008, 19 (05) :487-495

[17]

Pan X, 2004, WORLD J GASTROENTERO, V10, P1409

[18]

Raica M, 2007, NEOPLASMA, V54, P278

[19] The chick embryo chorioallantoic membrane as a model for tumor biology [J].

Ribatti, Domenico .

EXPERIMENTAL CELL RESEARCH, 2014, 328 (02) :314-324

[20]

Ribatti D, 2012, METHODS MOL BIOL, V843, P47, DOI 10.1007/978-1-61779-523-7_5

← 1 2 3 →